MODELING OF THE RESEARCH AND DEVELOPMENT PROCESS FOR A NEW DRUG TO ASSESS THE COSTS AND LIKELIHOOD OF SUCCESS AT EACH STAGE
https://doi.org/10.17073/2072-1633-2012-1-122-128
Abstract
The structure and functioning of clusters in the pharmaceutical industry were investigated here as the most effective structure to ensure superiority over the competition, innovation, education, the relationship between enterprises. The model of estimating the probability of successful development of new drugs and the cost of innovations for a Big-Pharma company is presented in this article, taking into account the interaction between pharmaceutical companies, costing each of the stages of R&D process, as well as the probability of passing each stage of development.
About the Authors
D. V. Shuvalova
Национальный исследовательский ядерный университет "МИФИ"
Russian Federation
Russian Federation
N. S. Rostovsky
Национальный исследовательский ядерный университет "МИФИ".
Russian Federation
Russian Federation
References
1. Федеральный портал РФ. URL: http://www.protown.ru/information/hide/4489.html.
2. Christian H.M. Ketels. Cluster-Based Economic Development. –USA: Harvard Business School, 2003. – P. 42.
3. Сайт компании Pfizer. URL: http://www.pfizer.com.
4. Усенко В.А. Фармацевтический маркетинг // Провизор. 1999. № 18.
5. Сайт журнала «Провизор». URL: http://www.provisor.com.ua (19.02.2012).
6. Christina M.L. Kelton, Margaret K. Pasquale, and Robert P. Rebelein. Using NAICS to Identify National Industry Cluster Templates for Applied Regional Analysis. – USA: 2006. – P. 16.
7. Christian H. M. Ketels. The Development of the cluster concept – present experiences and further developments. – USA: 2003. – P. 25.
8. Christian H. M. Ketels. The Development of the cluster concept – present experiences and further developments. – Germany: Paper prepared for NRW conference on clusters, 2003. –P. 25.
9. DiMasi J.A., Hansen R.W., H.G.Grabowski. The Price of Innovation: New Estimates of Drug Development Costs. – USA: Journal of Health Economics, 2003. – 185 p.
10. Henderson, Rebecca. Drug industry mergers won’t necessarily benefit R&D.: – USA: Journal of Economics, 2001. – P. 3.
11. Irving Arellano, Tania Fierro, Gabriela Morales, Carlos Sánchez, Gloria Pérez. Modeling the development of a biotechnological cluster. – Mexico: 2005. – P. 33.
12. Journal of Health Economics. New estimates of drug development costs. No 22 (2003). –USA, 2003. – P.151–185.
13. Roger L. Martin. Assessing the Strength of the Toronto Biopharmaceutical Cluster. – Canada: University of Toronto, 2004. – P. 23.
14. Айвазян С.А., Енюков И.С., Мешалкин Л.Д. Прикладная статистика. Основы моделирования и первичная обработка данных – М.: Финансы и статистика, 1983. – 471 c.
15. Сайт публикаций журнала «Еhe Journal of Business Chemistry». URL: http:// www.businesschemistry.org.
16. Стратегия развития фармацевтической промышленности Российской Федерации до 2020 года: проект. – M.: Минпромторг, 2009. – 62 с.
Review
For citations:
Shuvalova D.V., Rostovsky N.S. MODELING OF THE RESEARCH AND DEVELOPMENT PROCESS FOR A NEW DRUG TO ASSESS THE COSTS AND LIKELIHOOD OF SUCCESS AT EACH STAGE. Russian Journal of Industrial Economics. 2012;(1):122-128. (In Russ.) https://doi.org/10.17073/2072-1633-2012-1-122-128
Views:
664
Email this article 